Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

KYMRStrong4 of 9 basics passed

$112.40

+2.84%

Market cap $9.35B

$112.40

+2.84%

Market cap $9.35B

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives.

It is a $9.35B healthcare company. Revenue grew 134.8% over the last year, it currently loses money, and it holds more cash than debt.

Website: kymeratx.com
Location: Watertown, MA
Employees: 273
Sector: Healthcare

Share price · 3 years

$13.91 → $112.40+708.1%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $105M
Loss: spends more than it earns; -$300M
Free cash flow: cash left after running the business; -$238M
Net cash: more cash than debt; $766M
Shares: up 64% since 2021 — dilution; 84.5M
Volatility: beta vs the market — under 1 swings less; 2.04

Revenue, last 6 years

52-week range

Low $55.80$112.40High $127.31

Today's price is 79% of the way from the year's low to its high.

Valuation vs own history

P/S

89.0×

22%

P/B

6.2×

Share of the last ~5 years that was pricier than today (unusually expensive vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$4.16Mnet selling

Purchases$0

Sales$4.16M

Insiders trading, last 14d0 buy · 1 sell

Standing in Healthcare

Size$9.35Btop 93%
Revenue growth-6%top 92%
Net margin-285%top 95%
Return on equity-22%top 85%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong health; Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation20

P/E vs own historyn/a · 10/25
FCF yield-2.5% · 0/25
P/S89.0x · 0/25
EV/EBITDAn/a · 10/25

Growth0

Revenue CAGR-14.3% · 0/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROIC-38.3% · 0/25
ROE-21.5% · 0/25
Net margin-285.3% · 0/25
Operating margin-333.5% · 0/25

Health75

Altman Z47.67 · 25/25
Current ratio10.34 · 25/25
Interest coverage-1072.5x · 0/25
Net cash / debtNet cash · 25/25

Quality17

Piotroski F3/9 · 5/25
Beneish M-1.93 · 12/25
FCF conversionn/a · 0/25
Margin stabilityσ 200.8% · 0/25

Moat0

ROIC >12% years0/5 yrs · 0/25
Median gross margin-250.8% · 0/25
FCF-positive years1/6 yrs · 0/25
Worst-year net marginworst -794.0% · 0/25

How the scores work →

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$17 984 today — price return only

$39.2M revenue in FY2025

Revenue up 134.8% year over year

273 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

Revenue growing 134.8% year over year
Net cash position after subtracting debt from cash
Altman Z-Score 47.67 — low bankruptcy-risk zone

Watch-outs

Not profitable — 285.3% net margin
Negative free cash flow (-$238.0M)
Thin interest coverage (-1072.5×)
Loss-making in 6 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

4 of 9 checks passed

Revenue growing — the company sells more than a year ago+134.8% YoY
Profitable — makes more than it spends-$300M TTM
Profit growing — earnings are higher than last year-39.1% YoY
Generates cash — cash left after running and investing-$238M TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$9.35B market cap
Not printing shares — share count not ballooning — you keep your slice+64.1% shares over ~5y
Proven track record — years of profitability behind it0/6 profitable years
Financially stable — balance sheet not near distressAltman Z 47.7 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonKymera Therapeutics, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
KYMR this company	$9.3B	—	+134.8%	-285.3%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: KYMR vs LLY · KYMR vs JNJ · KYMR vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 10Buy 16Hold 4

Appendix · Financial records

The full statements behind this CV, FY2020–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $105M · net income -$300M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$105M

YoY 134.8%

Net income (TTM)

-$300M

Margin -285.3%

Operating margin

-333.5%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.0	0.1	0.0	0.1	0.0	0.0
Gross profit	—	-0.1	-0.1	-0.1	-0.2	-0.3
Operating income (EBIT)	-0.0	-0.1	-0.2	-0.2	-0.3	-0.3
Net income	-0.0	-0.1	-0.2	-0.1	-0.2	-0.3
EPS (diluted)	—	-1.95	-2.87	-2.64	-2.98	-3.69

Cash flowFree cash flow -$238M · operating cash flow -$237M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$238M

Margin -226.6%

Operating cash flow (TTM)

-$237M

FCF margin

-200.0%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	0.1	-0.1	-0.2	-0.1	-0.2	-0.2
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	0.1	-0.1	-0.2	-0.1	-0.2	-0.2
FCF margin	232.2%	-179.2%	-333.0%	-174.7%	-440.5%	-597.6%

Balance sheetAssets $1.74B · net cash $766M (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $1.74B of assets is financed

91%

Liabilities $163M — borrowed moneyEquity $1.58B — owners' stake

Cash vs debt

Total debt $82.3M − cash $848M = net cash $766M

Cash on hand covers all debt.

Altman Z-Score

47.67

Safe zone

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

-1072.5x

EBIT ÷ interest expense

ROE

-21.5%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.3	0.4	0.4	0.4	0.5	0.8
Total assets	0.5	0.6	0.6	0.6	1.0	1.7
Total liabilities	0.2	0.1	0.1	0.2	0.1	0.2
Total debt	—	0.0	0.0	0.1	0.1	0.1
Equity	0.3	0.5	0.5	0.4	0.8	1.6
Net debt	—	-0.4	-0.4	-0.3	-0.4	-0.8

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of KYMR on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $112.40 · market cap $9.35B.